NCT06459310 Pilot Study on Evaluating the Geroprotective Effect of Metformin
| NCT ID | NCT06459310 |
| Status | Recruiting |
| Phase | Phase 2 |
| Sponsor | Xuanwu Hospital, Beijing |
| Condition | Metformin |
| Study Type | INTERVENTIONAL |
| Enrollment | 130 participants |
| Start Date | 2024-06-30 |
| Primary Completion | 2026-09-30 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
In Phase 2, researchers evaluate early signs of effectiveness. You may be randomized to receive the active treatment or a comparator. Monitoring continues closely.
This trial targets 130 participants in total. It began in 2024-06-30 with a primary completion date of 2026-09-30.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The objective of this research is to assess the efficacy of oral metformin in mitigating the aging process in middle-aged and elderly males, to pinpoint sensitive indicators of human senescence, and to offer innovative frameworks and scientific insights for pharmaceutical interventions in aging.
Eligibility Criteria
Inclusion Criteria： 1. Male 2. Age 55-65; 18-28; 3. Able to understand and execute instructions; 4. After reading the consent form, be able to answer questions about the study and demonstrate understanding of the protocol; 5. Be able to participate in regular follow-up visits. Exclusion Criteria 1. Severe chronic or acute disease: cancer, clinically significant congestive heart failure, chronic obstructive pulmonary disease (COPD), previous or new-onset diabetes, inflammatory state, serum creatinine \>1.5 mg/dl , active liver disease, History of metabolic acidosis, poorly controlled hypertension, epilepsy, recent (within 3 months) cardiovascular events (MI, PTCA, CABG, stroke), severe renal insufficiency, inflammatory bowel disease, persistent glucocorticoids Treatment; neurological diseases such as dementia, AD, PD, etc.; infectious diseases such as HIV, hepatitis, tuberculosis, etc.; severe autoimmune diseases; 2. BMI\<18.5 or BMI\>30; 3. Persistent alcohol or drug abuse; 4. Treatment with drugs known to affect glucose metabolism (other diabetes drugs, systemic glucocorticoids, niacin); 5. Hypersensitivity to metformin or any component of the preparation; 6. Have taken metformin, low-dose aspirin, acarbose, vitamin C in the recent (3 months); 7. Unable to provide informed consent; 8. Other circumstances in which the researcher believes that the physical factors of the participants may adversely affect the research process or results.
Contact & Investigator
Guoguang Zhao, professor
STUDY CHAIR
Xuanwu Hospital, Beijing
Frequently Asked Questions
Who can join the NCT06459310 clinical trial?
This trial is open to male participants only, aged 18 Years or older, up to 65 Years, studying Metformin. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT06459310 trial and what does that mean for participants?
Phase 2 trials evaluate whether the treatment shows signs of effectiveness while continuing to monitor safety. More participants are enrolled than in Phase 1 to help refine the treatment protocol.
Is NCT06459310 currently recruiting?
Yes, NCT06459310 is actively recruiting participants. Contact the research team at gengll@xwhosp.org for enrollment information.
Where is the NCT06459310 trial being conducted?
This trial is being conducted at Beijing, China.
Who is sponsoring the NCT06459310 clinical trial?
NCT06459310 is sponsored by Xuanwu Hospital, Beijing. The principal investigator is Guoguang Zhao, professor at Xuanwu Hospital, Beijing. The trial plans to enroll 130 participants.